Welcome to our dedicated page for MEDICINOVA SEC filings (Ticker: MNOV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on MEDICINOVA's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into MEDICINOVA's regulatory disclosures and financial reporting.
Medicinova, Inc. (MNOV) – Form 4 insider filing
On 17 June 2025, director Carolyn Beaver was granted an option to purchase 20,000 shares of Medicinova common stock. The option’s exercise price is $1.26 per share and it will expire on 16 June 2035.
The award vests in four equal installments of 5,000 shares on the following dates, contingent on continued board service:
- 30 Sep 2025
- 31 Dec 2025
- 31 Mar 2026
- 30 Jun 2026
Following this grant, Beaver reports beneficial ownership of 20,000 derivative securities and no change in non-derivative holdings was disclosed.
The transaction was coded “A” (grant) and filed as a single-reporting-person Form 4 on 20 June 2025. No 10b5-1 plan was indicated.
Investor takeaway: This appears to be a routine equity incentive award to align director interests with shareholders; the 20,000-share size is modest relative to Medicinova’s outstanding share count and therefore immaterial from a dilution standpoint.